Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

BACKGROUND: Vaccine effectiveness studies have not differentiated the effect of the delta (B.1.617.2) variant and potential waning immunity in observed reductions in effectiveness against SARS-CoV-2 infections. We aimed to evaluate overall and variant-specific effectiveness of BNT162b2 (tozinameran,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tartof, Sara Y, Slezak, Jeff M, Fischer, Heidi, Hong, Vennis, Ackerson, Bradley K, Ranasinghe, Omesh N, Frankland, Timothy B, Ogun, Oluwaseye A, Zamparo, Joann M, Gray, Sharon, Valluri, Srinivas R, Pan, Kaije, Angulo, Frederick J, Jodar, Luis, McLaughlin, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489881/
https://www.ncbi.nlm.nih.gov/pubmed/34619098
http://dx.doi.org/10.1016/S0140-6736(21)02183-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489881/
https://www.ncbi.nlm.nih.gov/pubmed/34619098
http://dx.doi.org/10.1016/S0140-6736(21)02183-8

Ejemplares similares